Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
79 hedge funds and large institutions have $645M invested in Revance Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 19 reducing their positions, and 18 closing their positions.
554% more call options, than puts
Call options by funds: $6.6M | Put options by funds: $1.01M
89% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $655M → $645M (-$9.8M)
10% less funds holding
Funds holding: 88 → 79 (-9)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$18.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$5.39M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.34M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.68M |
| 5 |
Goldman Sachs
New York
|
+$2.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.61M |
| 2 |
Morgan Stanley
New York
|
-$1.7M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.65M |
| 4 |
Renaissance Technologies
New York
|
-$1.25M |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
-$1.09M |
RVNC Hedge Fund Activity: Q3 2015 in Review
79 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2015, worth a combined $645M — down 1.5% from $655M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of RVNC and 9 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 36 added.
The largest buyer was Canada Pension Plan Investment Board, opening a new position worth an estimated $18.5M. The largest seller was Millennium Management, cutting an estimated $2.61M.
- 79 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2015, down from 88 in Q2 2015.
- Funds reported $645M of Revance Therapeutics, Inc. stock for Q3 2015, down 1.5% quarter-over-quarter.
- 9 funds opened new Revance Therapeutics, Inc. positions in Q3 2015 and 18 closed out, a net change of -9 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2015 was Canada Pension Plan Investment Board, an estimated $18.5M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2015 was Millennium Management, an estimated $2.61M sold.
Based on aggregated 13F filings for Q3 2015.